Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing
Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Get 50% Off Elite

ICCC

Immucell Corp

Last Close
10.75
Nov 13 • 3:59 PM ET Dollar change+0.53 Percentage change(5.19%)
Aftermarket Close
10.75
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Overview Compare Short Interest Financials Options Filings Dilution
Healthcare Biotechnology USA Micro NASD
Nov 12, 4:41 PMImmuCell reports Q3 2026 revenue up 46% to $8.0 million and net income of $953,000, versus a year-earlier loss of $140,000
Peers: PAHC ELAN ZTS JAGX NEOG XBIT MCRB IDXX PETS CENT
 | Held by: VTI VXF IWC DFAC DFAT DXUV DCOR DFMC DFSU
Scroll to Statements
Index
-
Market Cap
97.63M
Enterprise Value
101.73M
Income
1.88M
Sales
33.21M
Book/sh
3.61
Cash/sh
0.87
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
73
IPO
May 05, 1987
P/E
53.27
Forward P/E
-
PEG
-
P/S
2.94
P/B
2.98
P/C
12.34
P/FCF
18.08
EV/EBITDA
20.47
EV/Sales
3.06
Quick Ratio
2.50
Current Ratio
4.61
Debt/Eq
0.37
LT Debt/Eq
0.32
Option/Short
No / Yes
EPS (ttm)
0.20
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
29.01% 4.06%
Sales past 3/5Y
14.19% 12.50%
EPS Y/Y TTM
-54.03%
Sales Y/Y TTM
19.59%
EPS Q/Q
764.94%
Sales Q/Q
46.02%
Earnings
Nov 12 AMC
EPS/Sales Surpr.
- -
Insider Own
37.62%
Insider Trans
0.23%
Inst Own
15.02%
Inst Trans
-0.96%
ROA
4.01%
ROE
6.01%
ROIC
4.34%
Gross Margin
40.83%
Oper. Margin
8.44%
Profit Margin
5.66%
SMA20
4.15%
SMA50
6.42%
SMA200
18.73%
Trades
Shs Outstand
9.09M
Shs Float
5.67M
Short Float
0.26%
Short Ratio
0.91
Short Interest
0.01M
52W High
12.10 -11.16%
52W Low
4.52 137.83%
Volatility
2.61% 2.66%
ATR (14)
0.35
RSI (14)
59.43
Beta
0.62
Rel Volume
2.51
Avg Volume
16.23K
Volume
40,761
Perf Week
9.69%
Perf Month
1.80%
Perf Quarter
10.82%
Perf Half Y
20.52%
Perf YTD
74.80%
Perf Year
77.69%
Perf 3Y
106.73%
Perf 5Y
16.56%
Perf 10Y
108.33%
Recom
-
Target Price
-
Prev Close
10.22
Price
10.75
Change %
5.19%
Show Previous News
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
te Boekhorst Paul Francis OlivPresident and CEOJun 18 '26Buy9.498,00075,96017,785Jun 22 08:33 AM
BRIGHAM MICHAEL FDirectorMar 20 '26Option Exercise5.8425,000146,000229,752Mar 24 07:57 PM
te Boekhorst Paul Francis OlivPresident and CEODec 03 '25Buy5.026,07730,5369,785Dec 03 04:14 PM
te Boekhorst Paul Francis OlivPresident and CEODec 02 '25Buy4.873,70818,0533,708Dec 03 04:14 PM
Tomsche David ScottDirectorNov 25 '25Buy4.761,6337,7814,740Nov 28 08:12 AM
Tomsche David ScottDirectorNov 25 '25Buy4.761,6337,77352,720Nov 28 08:12 AM
ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. It operates through the following segments: Scours and Mastitis. The Scours segment consists of the First Defense product line. The Mastitis segment includes the CMT product line consisting of reagents and equipment used for rapid cow-side testing to identify mastitic quarters by detecting elevated somatic cell counts. The company was founded in 1982 and is headquartered in Portland, ME.
PresidentMr. Paul F. Olivier Te Boekhorst
CFOMr. Timothy C. Fiori
Senior Vice President of Sales & MarketingMs. Bobbi Jo Brockmann
Director of Finance & Administration and ControllerMs. Elizabeth S. Toothaker
Senior Director of QualityMr. A. Gustavo Scaffa
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)